Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Antiangiogenic Therapy
13%
Arm
14%
Bevacizumab
48%
Biological Marker
10%
Biopsy Technique
14%
Blood Brain Barrier
15%
Cancer
7%
Central Nervous System
9%
Cerebrospinal Fluid
23%
Chemoradiotherapy
10%
Chemotherapy
41%
Clinical Trial
10%
Combination Chemotherapy
11%
Cranial Nerve
9%
Deterioration
8%
DNA Methyltransferase
8%
Drug Megadose
20%
Dynamic Contrast-Enhanced MRI
8%
Edema
19%
Ganglioglioma
76%
Genetics
17%
Glioblastoma
100%
Immune Checkpoint Inhibitor
7%
Injection
10%
Intracranial Tumor
21%
Irinotecan
15%
Karnofsky Performance Status
12%
Magnetic Resonance Imaging
46%
Metastatic Carcinoma
9%
Methotrexate
34%
Neoplasm
60%
Neurofibromatosis Type I
23%
Non-Hodgkin Lymphoma
14%
Oligodendroglioma
17%
Oncology
25%
Overall Survival
20%
Pharmacokinetics
9%
Plexiform Neurofibroma
15%
Positron Emission Tomography-Computed Tomography
11%
Principal Component Analysis
8%
Progression Free Survival
16%
Radiation Therapy
60%
Rituximab
12%
Spinal Nerve
9%
Temozolomide
54%
Treatment Outcome
9%
Treatment Response
14%
Tumor
20%
Tumor Progression
13%
Tumor Treating Fields
15%
Keyphrases
Adult Patients
9%
Anaplastic Oligodendroglioma
9%
Antiangiogenic Therapy
9%
Bevacizumab
74%
Bevacizumab Therapy
15%
Blood-brain Barrier Disruption
7%
Brain Tumor
14%
Cerebrospinal Fluid
15%
Chemoradiation
9%
Chemotherapy
29%
Complete Response
10%
Contrast Dynamics
9%
Dynamic Contrast-enhanced
26%
Dynamic Contrast-enhanced Magnetic Resonance Imaging (DCE-MRI)
28%
Glioblastoma
33%
Glioma
15%
Glioma Patients
16%
High-dose Methotrexate (HD-MTX)
15%
High-grade Glioma
40%
Immune Checkpoint Inhibitors
15%
Infiltrative Tumor
12%
Irinotecan
19%
Karnofsky Performance Status
9%
Lesion Volume
8%
Methotrexate
15%
Neurofibromatosis Type 1 (NF-1)
7%
Neurofibromatosis Type I
7%
Neurological Complications
9%
Newly Diagnosed Glioblastoma
9%
NRG Oncology
15%
Overall Survival
15%
Partial Response
8%
Phase I Study
23%
Plasma Volume
12%
Plexiform Neurofibroma
7%
Primary Brain Tumor
10%
Primary Central Nervous System Lymphoma (PCNSL)
17%
Progression-free Survival
22%
Progressive Disease
8%
Radiation Therapy
15%
Radiotherapy
17%
Randomized Phase II Trial
15%
Recurrent Glioblastoma
49%
Response Rate
11%
Rituximab
9%
Temozolomide
40%
Treatment Outcome
17%
Tumor
16%
Tumor Area
11%
VB-111
15%